LCAT


Also found in: Acronyms.

LCAT

LCAT

lecithin-cholesterol acyltransferase.

LCAT

abbreviation for lecithin-cholesterol acyltransferase. See lecithin-cholesterol acyltransferase deficiency.

LCAT

Lecithin:cholesterol acyl transferase, see there.

LCAT

latex cryptococcal antigen test; antibody coated latex beads used to detect polysaccharide antigens of Cryptococcus neoformans in body fluids.
References in periodicals archive ?
063 Electrophoresis broad[beta] [beta] Apoproteins B100, E B100 Core lipid (mass) TG=CE CE [much greater than] TG Subspeciation Large (A) Small (B) Modulation HL, CETP LCAT, HL, CETP Receptors LRP, LDLR LDLR Cholesterol 0 3 concentration--in fasting (mmol/l) Lipoproteins HDL Size (nm) 3-12 Density (g/ml) 1.
LCAT was assayed by measuring the rate of esterification using cholesterol labeled with radioactive carbon ([sup.
Familial LCAT deficiency is a rare, inherited condition that causes lipid accumulation in the eyes, red blood cells and kidneys.
LCAT is the key enzyme in mediating the esterification of cholesterol on circulating lipoproteins.
Increased catabolism of LpAI and LpAI:AII leading to low HDL cholesterol concentrations is characteristic of Tangier disease and LCAT deficiency.
The increase in HDL cholesterol after administration of ACP-501 supports the notion that LCAT is a bottleneck in the reverse cholesterol transport process," noted Auerbach.
Additionally, ACP-501 is being developed to treat familial LCAT deficiency (an orphan designated enzyme replacement therapy) and other diseases where LCAT activity is low.
Several patients with a genetic disorder in lipid metabolism, such as LCAT deficiency, had direct-method results that differed so markedly from the RMPs and from the typical values seen in these kinds of patients with HDL-C precipitation-based methods and a calculated LDL-C that they could have been misdiagnosed.
AlphaCore Pharma, a biopharmaceutical company, and Advanced Bioscience Laboratories (ABL), a biomedical contract research and manufacturing company, today announce funding from the National Institutes of Health, National Heart, Lung and Blood Institute (NHLBI) "Science Moving towards Research Translation and Therapy" (SMARTT) program, to manufacture recombinant human lecithin-cholesterol acyltransferase (rhLCAT) for the treatment of familial LCAT deficiency.